Skip to main content

Quality aspects of the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast.

Wärnberg F, Amini RM, Goldman M, Jirström K

Publication: Histopathology (2008) • Vol 53 • Page 642-9PMID: 19076680View on PubMed

Purpose

The purpose of this paper was to determine the effects of using tissue microarrays (TMAs) rather than whole sections to determine estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status of ductal carcinoma in situ (DCIS) of the breast.

Conclusion

Concordant case status between the whole section and the TMA was achieved in more than 80% of cases for HER2, ER and PR, with discordant results most often obtained in tumors of less than 10 mM or in cases with an intermediate (2+) HER2 score. The proportions of HER2 or ER positive tumors were similar when whole sections or TMAs were examined, but the proportion of PR positive tumors was higher when determined using TMAs. Generally the associations between ER, PR or HER2 status and nuclear grade and size were similar, regardless of whether TMAs or whole sections were examined. Differences in the proportions of recurrence based on HER2 and ER status were noted when TMAs were analyzed rather than whole sections.

Studies (1)

Purpose

The purpose of this study was to determine the effects of using TMAs rather than whole sections and lesion size on ER, PR and HER2 status in DCIS breast specimens. Prior to the study, ER, PR and HER2 status were determined on whole sections, and the remaining formalin-fixed paraffin-embedded (FFPE) blocks were stored for 8 y prior to array construction. For each specimen, two 1 mM cores were included in the array, and the whole sections were reevaluated to confirm ER, PR and HER2 status. HER2 status was determined using the HercepTest. ER and PR were considered positive if more than 10% of tumor cells stained. Antigen retrieval methods differed between initial analysis and this study.

Summary of Findings

Successful analysis of ER, PR and HER2 status was possible in 83.7% of cases with lesions greater than 10 mM but only 64.6% of cases with lesions less than or equal to 10 mM (p<0.0001). Concordant case status between whole sections and TMAs was achieved in 80.4, 84.2, and 81.5% of cases for HER2, ER and PR, respectively. Discordant results were obtained more often in tumors of less than 10 mM (20.1%) as opposed to those greater than 10 mM (12.1%). Discordant results were also obtained more often for cases with a HER2 score of 2+ compared to 0-1 or 3+ (p<0.0001). ER and PR showed more discordance in case status when less than 10% of cells stained as opposed to more, but this difference was not significant. While the proportions of HER2 or ER positive tumors were similar when whole sections or TMAs were examined, the proportion of PR positive tumors was 14% higher when determined using TMAs. Other than more PR positive grade 2 tumors in TMAs than whole sections, the associations between ER, PR or HER2 status and nuclear grade and size were similar, regardless of whether TMAs or whole sections were examined. Differences in the proportions of recurrence based on HER2 and ER status were noted when TMAs were analyzed rather than whole sections.
  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
    ProteinTissue microarray
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionBiomarker level
    11-66% of cells ER positive
    11-66% of cells PR positive
    HER2 score of 0-1
    HER2 score of 2+
    HER2 score of 3+
    Less than 10% of cells ER positive
    Less than 10% of cells PR positive
    More than 66% of cells ER positive
    More than 66% of cells PR positive
    PreaquisitionPrognostic factor
    Lesion <10 mM
    Lesion >10 mM
    Biospecimen Aliquots and ComponentsType of slide
    Tissue microarray
    Whole section
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    PR